Functional polymorphism of the promoter region of the prostacyclin synthase gene and severity of RSV infection in hospitalized children
Corresponding Author
Koichi Hashimoto
School of Medicine, Fukushima Medical University, Fukushima, Japan
Assistant Professor of Department of Pediatrics.
Department of Pediatrics, Fukushima Medical University, School of Medicine, 1st Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan.===Search for more papers by this authorKei Ishibashi
School of Medicine, Fukushima Medical University, Fukushima, Japan
Assistant Professor of Department of Urology.
Search for more papers by this authorTebeb Gebretsadik
Department of Biostatics, Vanderbilt University, School of Medicine, Nashville, Tennessee
Associate in Biostatics.
Search for more papers by this authorTina V. Hartert
Division of Allergy, Pulmonary, and Critical Care Medicine, Institute of Medicine and Public Health, Vanderbilt University, School of Medicine, Nashville, Tennessee
Associate Professor of Medicine.
Search for more papers by this authorAkihiro Yamamoto
School of Medicine, Fukushima Medical University, Fukushima, Japan
Faculty of Department of Cardiovascular Surgery.
Search for more papers by this authorTomohiro Nakayama
Department of Advanced Medical Science, Nihon University School of Medicine, Tokyo, Japan
Associate Professor of Division of Molecular Diagnostics.
Search for more papers by this authorKazutaka Ohashi
School of Medicine, Fukushima Medical University, Fukushima, Japan
Technical Assistant of Department of Microbiology.
Search for more papers by this authorHiroshi Sakata
Asahikawa Kosei Hospital, Asahikawa, Japan
Director of Pediatrics.
Search for more papers by this authorYukihiko Kawasaki
School of Medicine, Fukushima Medical University, Fukushima, Japan
Associate Professor of Department of Pediatrics.
Search for more papers by this authorMasahiko Katayose
Sohma General Hospital, Soma, Japan
Director of Pediatrics.
Search for more papers by this authorHiroko Sakuma
Hoshi General Hospital, Kohriyama, Japan
Director of Pediatrics.
Search for more papers by this authorHitoshi Suzuki
School of Medicine, Fukushima Medical University, Fukushima, Japan
Professor of Department of Pediatrics.
Search for more papers by this authorMitsuaki Hosoya
School of Medicine, Fukushima Medical University, Fukushima, Japan
Professor of Department of Pediatrics.
Search for more papers by this authorRay Stokes Peebles Jr.
Division of Allergy, Pulmonary, and Critical Care Medicine, Institute of Medicine and Public Health, Vanderbilt University, School of Medicine, Nashville, Tennessee
Associate Professor of Medicine.
Search for more papers by this authorTatsuo Suzutani
School of Medicine, Fukushima Medical University, Fukushima, Japan
Professor of Department of Microbiology.
Search for more papers by this authorCorresponding Author
Koichi Hashimoto
School of Medicine, Fukushima Medical University, Fukushima, Japan
Assistant Professor of Department of Pediatrics.
Department of Pediatrics, Fukushima Medical University, School of Medicine, 1st Hikarigaoka, Fukushima City, Fukushima 960-1295, Japan.===Search for more papers by this authorKei Ishibashi
School of Medicine, Fukushima Medical University, Fukushima, Japan
Assistant Professor of Department of Urology.
Search for more papers by this authorTebeb Gebretsadik
Department of Biostatics, Vanderbilt University, School of Medicine, Nashville, Tennessee
Associate in Biostatics.
Search for more papers by this authorTina V. Hartert
Division of Allergy, Pulmonary, and Critical Care Medicine, Institute of Medicine and Public Health, Vanderbilt University, School of Medicine, Nashville, Tennessee
Associate Professor of Medicine.
Search for more papers by this authorAkihiro Yamamoto
School of Medicine, Fukushima Medical University, Fukushima, Japan
Faculty of Department of Cardiovascular Surgery.
Search for more papers by this authorTomohiro Nakayama
Department of Advanced Medical Science, Nihon University School of Medicine, Tokyo, Japan
Associate Professor of Division of Molecular Diagnostics.
Search for more papers by this authorKazutaka Ohashi
School of Medicine, Fukushima Medical University, Fukushima, Japan
Technical Assistant of Department of Microbiology.
Search for more papers by this authorHiroshi Sakata
Asahikawa Kosei Hospital, Asahikawa, Japan
Director of Pediatrics.
Search for more papers by this authorYukihiko Kawasaki
School of Medicine, Fukushima Medical University, Fukushima, Japan
Associate Professor of Department of Pediatrics.
Search for more papers by this authorMasahiko Katayose
Sohma General Hospital, Soma, Japan
Director of Pediatrics.
Search for more papers by this authorHiroko Sakuma
Hoshi General Hospital, Kohriyama, Japan
Director of Pediatrics.
Search for more papers by this authorHitoshi Suzuki
School of Medicine, Fukushima Medical University, Fukushima, Japan
Professor of Department of Pediatrics.
Search for more papers by this authorMitsuaki Hosoya
School of Medicine, Fukushima Medical University, Fukushima, Japan
Professor of Department of Pediatrics.
Search for more papers by this authorRay Stokes Peebles Jr.
Division of Allergy, Pulmonary, and Critical Care Medicine, Institute of Medicine and Public Health, Vanderbilt University, School of Medicine, Nashville, Tennessee
Associate Professor of Medicine.
Search for more papers by this authorTatsuo Suzutani
School of Medicine, Fukushima Medical University, Fukushima, Japan
Professor of Department of Microbiology.
Search for more papers by this authorAbstract
Prostaglandin I2 (PGI2) protects against RSV-induced illness in mice. A variable-number tandem repeat (VNTR) polymorphism has been detected in the promoter region of the PGI2 synthase (PGIS) gene. We sought to determine if PGI2 concentrations or polymorphisms of the PGIS gene correlate with severity of RSV lower respiratory tract infections (LRTI) in human infants. VNTR polymorphisms were studied in 81 previously healthy children between birth and 12 months of age who were hospitalized for LRTI due to RSV and 98 healthy adult control subjects. The severity of RSV infection was quantified using a clinical scoring system, and infant urine samples were collected during the acute illness for measurement of the urinary metabolite of PGI2. There were no significant differences in the overall distribution of alleles and genotypes between infants with RSV LRTI and the control subjects. The severity of RSV infection significantly inversely correlated with urinary PGI2 metabolite concentrations. The urinary PGI2 metabolite concentration correlated with the number of VNTR. The presence of a genotype with a low number VNTR repeats significantly correlated with the most severe RSV LRTI, and genotypes with the highest number of VNTR correlated with the least severe RSV LRTI. A functional polymorphism in the promoter region of the PGIS gene is associated with both significant differences in urinary PGI2 concentrations during RSV LRTI, and severity of RSV infection in previously healthy infants. J. Med. Virol. 80:2015–2022, 2008. © 2008 Wiley-Liss, Inc.
Supporting Information
Additional supporting information may be found in the online version of this article.
| Filename | Description |
|---|---|
| jmv_21318_sm_suppInform.doc31.5 KB | Supplementary Information |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- Agresti A, Min Y. 2002. Unconditional small-sample confidence intervals for the odds ratio. Biostatistics (Oxford, England) 3: 379–386.
- Anderson LJ, Hierholzer JC, Tsou C, Hendry RM, Fernie BF, Stone Y, McIntosh K. 1985. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 151: 626–633.
- Aurivillius M, Oymar K, Oxelius VA. 2005. Immunoglobulin heavy G2 chain (IGHG2) gene restriction in the development of severe respiratory syncytial virus infection. Acta Paediatr 94: 414–418.
- Carroll KN, Gebretsadik T, Griffin MR, Wu P, Dupont WD, Mitchel EF, Enriquez R, Hartert TV. 2008. Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan. Pediatrics 122: 58–64.
- Chevalier D, Cauffiez C, Bernard C, Lo-Guidice JM, Allorge D, Fazio F, Ferrari N, Libersa C, Lhermitte M, D'Halluin JC, Broly F. 2001. Characterization of new mutations in the coding sequence and 5′-untranslated region of the human prostacylcin synthase gene (CYP8A1). Hum Genet 108: 148–155.
- Choi EH, Lee HJ, Yoo T, Chanock SJ. 2002. A common haplotype of interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children. J Infect Dis 186: 1207–1211.
- Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. 1998. Cyclooxygenase in biology and disease. FASEB J 12: 1063–1073.
- Eisenhut T, Sinha B, Grottrup-Wolfers E, Semmler J, Siess W, Endres S. 1993. Prostacyclin analogs suppress the synthesis of tumor necrosis factor-alpha in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology 26: 259–264.
- Fodha I, Vabret A, Ghedira L, Seboui H, Chouchane S, Dewar J, Gueddiche N, Trabelsi A, Boujaafar N, Freymuth F. 2007. Respiratory syncytial virus infections in hospitalized infants: Association between viral load, virus subgroup, and disease severity. J Med Virol 79: 1951–1958.
- Fong CY, Pang L, Holland E, Knox AJ. 2000. TGF-beta1 stimulates IL-8 release, COX-2 expression, and PGE(2) release in human airway smooth muscle cells. Am J Physiol 279: L201–L207.
- Gentile DA, Doyle WJ, Zeevi A, Howe-Adams J, Kapadia S, Trecki J, Skoner DP. 2003. Cytokine gene polymorphisms moderate illness severity in infants with respiratory syncytial virus infection. Hum Immunol 64: 338–344.
- Gershwin LJ, Giri SN. 1992. Effects of allergen challenge on plasma concentrations of prostaglandins, thromboxane B2, and histamine in calves infected with bovine respiratory syncytial virus. Am J Vet Res 53: 1670–1674.
- Gershwin LJ, Giri SN, Stewart RS, Chen J. 1989. Prostaglandin and thromboxane concentrations in plasma and lung lavage fluids during sequential infection of vaccinated and nonvaccinated calves with bovine respiratory syncytial virus. Am J Vet Res 50: 1254–1262.
- Glezen WP, Taber LH, Frank AL, Kasel JA. 1986. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child (1960) 140: 543–546.
- Graham BS, Bunton LA, Wright PF, Karzon DT. 1991. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 88: 1026–1033.
- Hall CB. 2001. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 344: 1917–1928.
- Hashimoto K, Graham BS, Geraci MW, FitzGerald GA, Egan K, Zhou W, Goleniewska K, O'Neal JF, Morrow JD, Durbin RK, Wright PF, Collins RD, Suzutani T, Peebles RS, Jr. 2004. Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness. J Virol 78: 10303–10309.
- Henrickson KJ, Hoover S, Kehl KS, Hua W. 2004. National disease burden of respiratory viruses detected in children by polymerase chain reaction. Pediatr Infect Dis J 23: S11–S18.
- Hoebee B, Rietveld E, Bont L, Oosten M, Hodemaekers HM, Nagelkerke NJ, Neijens HJ, Kimpen JL, Kimman TG. 2003. Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor alpha polymorphisms. J Infect Dis 187: 2–11.
- Hoebee B, Bont L, Rietveld E, van Oosten M, Hodemaekers HM, Nagelkerke NJ, Neijens HJ, Kimpen JL, Kimman TG. 2004. Influence of promoter variants of interleukin-10, interleukin-9, and tumor necrosis factor-alpha genes on respiratory syncytial virus bronchiolitis. J Infect Dis 189: 239–247.
- Hull J, Ackerman H, Isles K, Usen S, Pinder M, Thomson A, Kwiatkowski D. 2001. Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus. Am J Hum Genet 69: 413–419.
- Iwai N, Katsuya T, Ishikawa K, Mannami T, Ogata J, Higaki J, Ogihara T, Tanabe T, Baba S. 1999. Human prostacyclin synthase gene and hypertension : The Suita Study. Circulation 100: 2231–2236.
- Jaffar Z, Wan KS, Roberts K. 2002. A key role for prostaglandin I2 in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen. J Immunol 169: 5997–6004.
- Janssen R, Bont L, Siezen CL, Hodemaekers HM, Ermers MJ, Doornbos G, van't Slot R, Wijmenga C, Goeman JJ, Kimpen JL, van Houwelingen HC, Kimman TG, Hoebee B. 2007. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis 196: 826–834.
- Lahti M, Lofgren J, Marttila R, Renko M, Klaavuniemi T, Haataja R, Ramet M, Hallman M. 2002. Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection. Pediatr Res 51: 696–699.
- Laporte JD, Moore PE, Abraham JH, Maksym GN, Fabry B, Panettieri RA, Jr., Shore SA. 1999. Role of ERK MAP kinases in responses of cultured human airway smooth muscle cells to IL-1beta. Am J Physiol 277: L943–L951.
- Laporte JD, Moore PE, Lahiri T, Schwartzman IN, Panettieri RA, Jr., Shore SA. 2000. p38 MAP kinase regulates IL-1 beta responses in cultured airway smooth muscle cells. Am J Physiol 279: L932–941.
- Leader S, Kohlhase K. 2002. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J 21: 629–632.
- Lofgren J, Ramet M, Renko M, Marttila R, Hallman M. 2002. Association between surfactant protein A gene locus and severe respiratory syncytial virus infection in infants. J Infect Dis 185: 283–289.
- Luttmann W, Herzog V, Virchow JC, Jr., Matthys H, Thierauch KH, Kroegel C. 1996. Prostacyclin modulates granulocyte/macrophage colony-stimulating factor release by human blood mononuclear cells. Pulm Pharmacol 9: 43–48.
- Luttmann W, Herzog V, Matthys H, Thierauch KH, Virchow JC, Kroegel C. 1999. Modulation of cytokine release from mononuclear cells by prostacyclin, IL-4 and IL-13. Cytokine 11: 127–133.
- Martinello RA, Chen MD, Weibel C, Kahn JS. 2002. Correlation between respiratory syncytial virus genotype and severity of illness. J Infect Dis 186: 839–842.
- Meja KK, Barnes PJ, Giembycz MA. 1997. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation. Br J Pharmacol 122: 149–157.
- Miyata A, Hara S, Yokoyama C, Inoue H, Ullrich V, Tanabe T. 1994. Molecular cloning and expression of human prostacyclin synthase. Biochem Biophys Res Commun 200: 1728–1734.
- Mufson MA, Orvell C, Rafnar B, Norrby E. 1985. Two distinct subtypes of human respiratory syncytial virus. J Gen Virol 66: 2111–2124.
- Nagao K, Tanaka H, Komai M, Masuda T, Narumiya S, Nagai H. 2003. Role of prostaglandin I2 in airway remodeling induced by repeated allergen challenge in mice. Am J Respir Cell Mol Biol 29: 314–320.
- Nakayama T, Soma M, Izumi Y, Kanmatsuse K. 1996. Organization of the human prostacyclin synthase gene. Biochem Biophys Res Commun 221: 803–806.
- Nakayama T, Soma M, Rehemudula D, Takahashi Y, Tobe H, Satoh M, Uwabo J, Kunimoto M, Kanmatsuse K. 2000. Association of 5′ upstream promoter region of prostacyclin synthase gene variant with cerebral infarction. Am J Hypertens 13: 1263–1267.
- Openshaw PJ, Tregoning JS. 2005. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 18: 541–555.
- Pang L. 2001. COX-2 expression in asthmatic airways: The story so far. Thorax 56: 335–336.
- Raychaudhuri B, Malur A, Bonfield TL, Abraham S, Schilz RJ, Farver CF, Kavuru MS, Arroliga AC, Thomassen MJ. 2002. The prostacyclin analogue treprostinil blocks NFkappaB nuclear translocation in human alveolar macrophages. J Biol Chem 277: 33344–33348.
- Richardson JY, Ottolini MG, Pletneva L, Boukhvalova M, Zhang S, Vogel SN, Prince GA, Blanco JC. 2005. Respiratory syncytial virus (RSV) infection induces cyclooxygenase 2: A potential target for RSV therapy. J Immunol 174: 4356–4364.
- Rodriguez WJ, Gruber WC, Groothuis JR, Simoes EA, Rosas AJ, Lepow M, Kramer A, Hemming V. 1997. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 100: 937–942.
- Singh AM, Moore PE, Gern JE, Lemanske RF, Jr., Hartert TV. 2007. Bronchiolitis to asthma: A review and call for studies of gene-virus interactions in asthma causation. Am J Respir Crit Care Med 175: 108–119.
- Smith WL. 1992. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263: F181–F191.
- Takahashi Y, Tokuoka S, Masuda T, Hirano Y, Nagao M, Tanaka H, Inagaki N, Narumiya S, Nagai H. 2002. Augmentation of allergic inflammation in prostanoid IP receptor deficient mice. Br J Pharmacol 137: 315–322.
- Tsutsumi H, Onuma M, Suga K, Honjo T, Chiba Y, Chiba S, Ogra PL. 1988. Occurrence of respiratory syncytial virus subgroup A and B strains in Japan, 1980 to 1987. J Clin Microbiol 26: 1171–1174.
- van Schaik SM, Obot N, Enhorning G, Hintz K, Gross K, Hancock GE, Stack AM, Welliver RC. 2000. Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice. J Med Virol 62: 257–266.
- Welliver TP, Garofalo RP, Hosakote Y, Hintz KH, Avendano L, Sanchez K, Velozo L, Jafri H, Chavez-Bueno S, Ogra PL, McKinney L, Reed JL, Welliver RCSr. 2007. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 195: 1126–1136.
- Zavagno G, Jaffe B, Esteban M. 1987. Role of prostaglandins and non-steroid anti-inflammatory drugs in the pathogenicity of vaccinia virus. J Gen Virol 68: 593–600.
- Zhou W, Hashimoto K, Goleniewska K, O'Neal JF, Ji S, Blackwell TS, Fitzgerald GA, Egan KM, Geraci MW, Peebles RS, Jr. 2007. Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J Immunol 178: 702–710.
Citing Literature
